[Combined treatment with beta-receptor blocker pindolol and diureticum trichlormethiazidum in patients with essential hypertony in stadium II WHO (author's transl))].
A double blind study was performed concerning effects and endurance of a combined therapy with beta-receptor blocker Pindolol (LB 46 Visken Sandoz/2 X 2 tabletes per 5 mg daily and Trichlormethiazidum Eurinol Spofa 3-dicholor-methyl-6-chlor-7-sulfamoyl 3,4-dihydro-1,2, 4-benzothiadiazin-1, 1-dyoxydum) 1 X1 tablet per 4 mg daily in 74 patients with essential hypertony in stadium II WHO. Reduction of the systolic as well as the diastolic blood pressure was already highly significant after the first two weeks of treatment (p less than 0.05). Heart frequency dropped from the average of 86,6 +/-8,6 per minute to 74 +/-16.8 per minute. All patients endured the medication very well.
D001794:Blood Pressure; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D010869:Pindolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011674:Pulse; D013997:Time Factors; D014237:Trichlormethiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010869:Pindolol; D014237:Trichlormethiazide
Die Anwendung des Betarezeptorenhemmers Pindolol mit dem Diuretikum Trichlormethiazidum) bei Kranken mit essentieller Hypertonie im Standium II WHO.